🏭 The plant, which specializes in biotechnology, had faced uncertainty after the European Commission terminated its COVID-19 vaccine contract. ❌
🌱 However, the Scottish government has now amended its grant to support the plant’s reopening. 💪
👥 This is good news for the local economy and the biotechnology industry. 🌍
Introduction:
Valneva, a biotech company based in Scotland, has received a £14.3 million grant from the UK government to expand its manufacturing capabilities for COVID-19 vaccines. The funding will allow the company to reconfigure its plant in Livingston, Scotland, to produce up to 60 million doses of its vaccine candidate, VLA2001, in the second half of 2022.
- The UK government has reworked a previous agreement with Valneva to provide additional funding and secure the supply of COVID-19 vaccines.
- The funding will support the expansion and reconfiguration of Valneva’s plant in Scotland to increase production capacity.
- Valneva plans to produce up to 60 million doses of its COVID-19 vaccine candidate, VLA2001, in the second half of 2022.
- The agreement includes an option for the UK government to purchase an additional 130 million doses of the vaccine candidate for 2023 and 2024.
- This funding will boost the UK’s vaccine manufacturing capabilities and contribute to global efforts to ensure equitable access to COVID-19 vaccines.
Conclusion:
Valneva’s receipt of a £14.3 million grant from the UK government will enable the company to expand its manufacturing capabilities for COVID-19 vaccines. This funding represents a significant step in increasing vaccine production capacity and ensuring the availability of vaccines in the UK and globally. The agreement also highlights the UK government’s commitment to supporting domestic vaccine manufacturing and contributing to the global effort to combat the COVID-19 pandemic.
